Cocrystal Pharma's Norovirus Antiviral CDI-988 Shows Potent Activity Against Emerging GII.17 Variants

Cocrystal Pharma, Inc.

CDI-988 demonstrated potent binding to conserved region of GII.17 protease, comparable to activity against GII.4 variants.
Company plans to initiate a human norovirus challenge study in 2025 for prevention and treatment.
Phase 1 study showed favorable safety and tolerability of CDI-988 in healthy adults.
Norovirus causes ~685 million cases and ~50,000 child deaths annually with $60B societal cost.
No approved antiviral treatments or vaccines for norovirus exist.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.